BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND KMT2D, ENSG00000167548, 8085, MLL2 AND Treatment
19 results:

  • 1. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
    Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
    Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.
    Wang S; Gu Z; Zhu L; Han Y; Yu H; Fang W; Han B
    Chin Med J (Engl); 2023 Nov; 136(22):2712-2721. PubMed ID: 37749819
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine tumors and Metastases.
    Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
    Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular and immunohistochemical comparison between primary gastrointestinal mucosal melanomas and atypical gastrointestinal stromal tumors.
    Song IH; Sung YE; Kang J; Lee A; Lee SH
    Pathol Res Pract; 2022 Dec; 240():154189. PubMed ID: 36327823
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Orbital metastasis from neuroendocrine tumour: Case report and literature review.
    Albanese G; Harieaswar S; Sampath R
    Eur J Ophthalmol; 2022 Sep; 32(5):2498-2504. PubMed ID: 34787007
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1.
    Klonou A; Korkolopoulou P; Gargalionis AN; Kanakoglou DS; Katifelis H; Gazouli M; Chlamydas S; Mitsios A; Kalamatianos T; Stranjalis G; Themistocleous MS; Papavassiliou KA; Sgouros S; Papavassiliou AG; Piperi C
    Neurotherapeutics; 2021 Jul; 18(3):2073-2090. PubMed ID: 34296393
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical and mutational profiles of adult medulloblastoma groups.
    Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study.
    Luo L; Lin L; Zhang X; Cai Q; Zhao H; Xu C; Cong Q
    Biomed Res Int; 2020; 2020():1314967. PubMed ID: 31998776
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
    Pillai S; Gopalan V; Smith RA; Lam AK
    Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Contemporary management of stage I and II seminoma.
    Chung P; Warde P
    Curr Urol Rep; 2013 Oct; 14(5):525-33. PubMed ID: 23949632
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Dissecting the genomic complexity underlying medulloblastoma.
    Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
    Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
    Alexandrescu DT
    Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Current treatment options for clinical stage I seminoma.
    Stephenson AJ
    World J Urol; 2009 Aug; 27(4):427-32. PubMed ID: 19370354
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. treatment options, prognostic factors and selection of treatment in stage I seminoma.
    Martin J; Chung P; Warde P
    Onkologie; 2006 Dec; 29(12):592-8. PubMed ID: 17202831
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Diagnosis and management of tumors of the adrenal medulla.
    Ilias I; Pacak K
    Horm Metab Res; 2005 Dec; 37(12):717-21. PubMed ID: 16372223
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor].
    Heidenreich A; Krege S; Flasshove M
    Urologe A; 2004 Dec; 43(12):1521-30. PubMed ID: 15592709
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Results of fertility preserving operations in malignant ovarian tumors].
    Kleine W
    Zentralbl Gynakol; 1996; 118(6):317-21. PubMed ID: 8768006
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. treatment of solid tumors should obligatorily be combined with the in vivo codepletion of tumor-protecting, CD8+/HLA-DR(+)-suppressor T cells by alloreactive donor T cells whose preprogrammed cell death allows a high GvL-effect before GvHD can be established. Results of animal experiments, including more than 6000 mice.
    Leskovar P; Bielmeier J
    Pflugers Arch; 1996; 431(6 Suppl 2):R229-30. PubMed ID: 8739348
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.